Ганаксолон
Многоцентровое двойное слепое рандомизированное плацебо-контролируемое исследование эффективности и безопасности ганаксолона в качестве адъювантной терапии у пациентов с фармакорезистентными парциальными припадками с последующим длительным периодом открытого лечения
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/692/2013-11-01/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 120 чел. в стране «Россия».
- Центров в реестре: 9 в 6 городах. Список — ниже на странице.
- Плановая дата окончания (07.2017) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 24
Критерии включения
- Able to give informed consent in writing, or have a legally authorized representative able to do so
- Willing to enter and participate for the full term of the double blind phase and willing to enter into the open-label phase
- Male or female outpatients > 18 years of age
- Have a confident diagnosis of drug-resistant epilepsy with partial-onset seizures (POS), with or without secondary generalization, for ≥2 years. Have residual POS despite having been treated in the past with at least 2 approved anti-epilepsy drugs (AEDs) either alone or in combination
- Based on history, participants would be anticipated to have at least 3 POS during each 4-week Baseline period and unlikely to have 21 or more consecutive POS-free days
- Currently being treated and maintained with a stable regimen of 1, 2, or 3 AEDs
- Able and willing to maintain daily seizure calendar
- Able and willing to take drug with food twice daily
- Sexually active women of childbearing potential must use acceptable birth control and have a negative pregnancy test at all visits
Критерии невключения
- Have had previous exposure to ganaxolone
- Known sensitivity or allergy to any component in the study drug, progesterone, or other related steroid compounds
- Exposure to any investigational drug or device <30 days prior to screening, or plans to take another investigational drug at any time during the study
- Time of onset of epilepsy treatment <2 years prior to enrollment
- Have generalized epilepsy, such as Lennox-Gastaut syndrome, juvenile myoclonic epilepsy, absence epilepsy, or non-epileptic seizures within the last 12- month period prior to study entry
- Have less than 3 POS seizures in a 28-day period or more than 21 consecutive seizure-free days during the Baseline period
- Have only simple partial seizures without any observable motor component
- Have innumerable seizures or status epilepticus within the last 12-months prior to screening
- Have more than 100 POS per 4-week Baseline period
- Have seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or central nervous system (CNS) disease deemed progressive, metabolic illness, or progressive degenerative disease
- Current use of vigabatrin is not permitted. If prior use of vigabatrin, must have documented stable visual fields
- Current use of ezogabine is not permitted. If prior use, must have been off the medication for at least 3 months prior to screening and have had documented normal fundoscopic exam by ophthalmologist
- Are planning surgery, or to be evaluated for surgery, during the double-blind phase to control seizures including VNS implantation
- Are suffering from acute or progressive neurological disease, moderate or severe psychiatric disease, or severe mental abnormalities that are likely to require changes in drug therapy during the double-blind portion of the study or interfere with the objectives of the study or the ability to adhere to the protocol requirements
- Have a history of an actual suicide attempt in the last 5 years or more than 1 lifetime suicide attempt
- Have a positive urine drug screen at Screening or meet criteria for current or historical Substance Use Disorder (DSM-V criteria) within the past 5 years.
- Have any medical condition that, in the investigator's judgment, is considered to be clinically significant and could potentially affect participant safety or study outcome, including but not limited to: clinically significant cardiac, renal, pulmonary, gastrointestinal, hematologic or hepatic conditions; or a condition that affects the absorption, distribution, metabolism or excretion of drugs
- Have elevated ALT (SGPT) or AST (SGOT) greater than 3 times upper limits of normal, or total bilirubin greater than 1.5 times ULN
- Have a history of malignancy within the past 2 years, with the exception of basal cell carcinoma
- Are currently following or planning to follow a ketogenic diet
- Use of dietary supplements or herbal preparations are not permitted if participant has been using them consistently for less than 6 months prior to screening, or does not plan on remaining on stable doses for the duration of the double blind phase. Use of St. John's Wort is not permitted
- Females who are pregnant, currently breastfeeding or planning to become pregnant during the duration of the study
- A history of chronic noncompliance with drug regimens
- Inability to withhold grapefruit and grapefruit juice from diet during the entire clinical trial
Источник: ClinicalTrials.gov, NCT01963208 · запись обновлена в реестре 14 февраля 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 15
- Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period — Baseline and Week 14
Цель исследования
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
Области и заболевания
Где проходит
9 центров в 6 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 692 от 01.11.2013 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01963208 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 4802 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.